Deals

Coller emerges as sole lead on Verdane’s €600m-plus multi-asset CV

StepStone co-underwrote the transaction, which includes Arrive Group, marking the second time a PE firm has moved its exposure to this asset into a CV.

Ares leads on Baird Capital’s life sciences single-asset CV

The continuation fund for Blue Matter Consulting is ‘one of those CVs that’s happening for the right reasons’, says Baird partner Michael Holgate.

CV performance to diverge as asset quality widens – StepStone

The GP-led market is expected to see a more ‘mixed-quality’ set of assets come through, according to StepStone’s Philippe Ferneini.

LPs look to blindpool fund side letters for more visibility on CVs: Morgan Lewis – updated

Some LPs are finding themselves as forced sellers in CVs because of the length of time given in election periods.

Lexington leads MetLife’s $1bn managed fund deal

The insurer worked with Evercore to shop a $1.8bn portfolio under the name Project Trident, Secondaries Investor has learned.

Nordic Capital mulls another multi-asset CV

If the deal goes ahead, the CV is anticipated to be in the region of €2bn to €2.5bn, Secondaries Investor understands.

Pantheon leads on sustainability-focused Alder’s €250m CV

Tech-focused Nordics investor Alder has moved two assets into an Article 9 continuation vehicle.

Arcmont’s Ares-led $2.5bn CV in ‘absolute sweet spot’

Arcmont sees ‘an enormous benefit’ to the burgeoning credit secondaries market and is open to dealing with its traditional private debt competitors in the future, CEO Anthony Fobel tells Secondaries Investor.

Carlyle AlpInvest leads on TowerBrook’s CV for EisnerAmper

TowerBrook has ‘spent considerable money, time and resources’ transforming the professional services business across its four-plus year hold, managing director Walter Weil tells Secondaries Investor.

QHP’s pharma single-asset delivers 10x for selling LPs

This is at least the second time the mid-market healthcare-focused firm has run a CV to extend its hold of a top-performing asset.